The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC).
Jennifer M. Specht
Research Funding - Genentech; Pfizer
Brenda F. Kurland
No relevant relationships to disclose
Hannah M. Linden
No relevant relationships to disclose
Julie Gralow
Research Funding - Amgen; Novartis; Roche/Genentech
Vijayakrishna K. Gadi
No relevant relationships to disclose
Georgiana Kehr Ellis
No relevant relationships to disclose
Eve T. Rodler
No relevant relationships to disclose
Xiaoyu Chai
No relevant relationships to disclose
Jinny Eun
No relevant relationships to disclose
Ursa Abigail Brown-Glaberman
No relevant relationships to disclose
Robert B. Livingston
No relevant relationships to disclose